Report cover image

Retinitis Pigmentosa (RP) - Competitive Landscape

Publisher GlobalData
Published Mar 31, 2024
Length 73 Pages
SKU # GBDT18789308

Description

Retinitis Pigmentosa (RP) - Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in RP therapeutics.
  • More than 1,000,000 diagnosed prevalent cases of RP are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for RP.
  • The treatment guidelines for RP have been well established globally. Roche’s Luxturna (voretigene neparvovec) dominate the RP market.
  • Majority of RP pipeline assets are protein and peptide activator, followed by receptor activator.
  • A total of 107 clinical trials were initiated for RP in the past 10 years, Phase III trials made up 12.15% of the total trials.
  • Licensing agreement was the predominant deal type in South America, Africa, Asia-Pacific and North America. In Europe, partnership deals were notably widespread.
Scope

GlobalData’s RP: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the RP market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RP market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

73 Pages
  • Report Scope
  • Key Findings
    • Disease Etiology
    • Epidemiology Overview - Diagnosed Prevalent Cases of RP in 2024 and 2029
    • Treatment Guidelines
    • Treatment Algorithm
    • Marketed Drugs - Leading Marketed Drugs in RP
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drug Profile - Roche's Luxturna
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Luxturna
    • Pipeline Drugs Overview - Phase III and Phase II Pipeline Drugs in RP
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in RP
    • Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in Ophthalmology and RP
    • Clinical Trials in RP - Historical Overview
    • Clinical Trials in RP - Overview by Phase
    • Clinical Trials in RP - Overview by Status
    • Clinical Trials in RP - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in RP - Trials with a Virtual Component
    • Clinical Trials in RP - Geographic Overview
    • Clinical Trials in RP - Single-Country and Multinational Trials by Region
    • Clinical Trials in RP - Top Sponsors with Breakdown by Phase
    • Clinical Trials in RP - Top Sponsors with Breakdown by Status
    • Clinical Trials in RP - Overview by Endpoint Status
    • Clinical Trials in RP - Overview by Race and Ethnicity
    • Clinical Trials in RP - Enrollment Data
    • Clinical Trials in RP - Overview of Sites by Geography
    • Clinical Trials in RP - Top 20 Countries for Trial Sites
    • Clinical Trials in RP - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for RP
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in RP by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in RP
    • Commercial Assessment - Key Market Players in RP
    • Future Market Catalysts - Upcoming Market Catalysts in RP
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.